Known targets — ChEMBL curated mechanism
SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Riluzole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A known ✓ | P35499 | 4/20 | 1.00 |
| ▸ | SCN9A known ✓ | Q15858 | 2/20 | 1.00 |
| ▸ | SCN5A known ✓ | Q14524 | 1/20 | 1.00 |
| ▸ | SCN2A known ✓ | Q99250 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 6/20 | 1.00 |
| ▸ | NPC1 | O15118 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 1.00 |
| ▸ | TP53 | P04637 | 3/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | PKM | P14618 | 2/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Riluzole SCHEMBL8913448 | 1.00 | RAB9A (1.00) | RAB9ANPC1CYP3A4SCN4ASMN1; SMN2 | |
| Riluzole SCHEMBL29359189 | 1.00 | RAB9A (1.00) | RAB9ANPC1CYP3A4SCN4ASMN1; SMN2 | |
| Riluzole SCHEMBL5053829 | 1.00 | RAB9A (1.00) | RAB9ANPC1CYP3A4SCN4ASMN1; SMN2 | |
| Riluzole SCHEMBL29079504 | 0.98 | RAB9A (0.97) | RAB9ANPC1CYP3A4SCN4ASMN1; SMN2 | |
| Riluzole SCHEMBL29079505 | 0.98 | RAB9A (0.97) | RAB9ANPC1CYP3A4SCN4ASMN1; SMN2 | |
| Riluzole SCHEMBL23610347 | 0.98 | RAB9A (0.97) | RAB9ANPC1CYP3A4SCN4ASMN1; SMN2 | |
| Riluzole SCHEMBL27787859 | 0.98 | RAB9A (0.97) | RAB9ANPC1CYP3A4SCN4ASMN1; SMN2 | |
| Riluzole SCHEMBL1394245 | 0.98 | RAB9A (1.00) | RAB9ANPC1CYP3A4SCN4ASMN1; SMN2 | |
| Riluzole SCHEMBL4443848 | 0.90 | RAB9A (0.82) | RAB9ANPC1CYP3A4SCN4ASMN1; SMN2 | |
| Riluzole SCHEMBL9218955 | 0.89 | CYP3A4 (0.80) | RAB9ANPC1CYP3A4SCN4ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 22805 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| US-20260137680-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | US | claimed |
| US-20260138973-A1 | SUBSTITUTED PYRIDINES FOR USE IN TREATING OR PREVENTING INFLAMMATORY DISEASES OR DISEASES ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE | SITRYX THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | US | claimed |
| CN-122056258-A | Beta-methylamino-L-alanine-induced amyotrophic lateral sclerosis-based zebra fish model, and construction method and application thereof | 青岛奔月生物技术有限公司 | 2026-05-19 | — | — | CN | claimed |
| CN-122028926-A | Combined Chinese and Western medicine therapy for treating amyotrophic lateral sclerosis patient | 协峰分子医疗有限公司 | 2026-05-12 | — | — | CN | claimed |
| CN-122017089-A | Method for simultaneously detecting concentration of riluzole and edaravone | 杭州市老年病医院 | 2026-05-12 | — | — | CN | claimed |
| US-12617762-B2 | Carboxy derivatives with antiinflamatory properties | SITRYX THERAPEUTICS LIMITED (GB) | 2026-05-05 | — | — | US | claimed |
| WO-2026088112-A1 | COMBINATION THERAPIES WITH AR-DEGRADING AGENTS AND PSMA-TARGETING RADIOLIGANDS | NOVARTIS AG (CH) | 2026-04-30 | — | — | WO | claimed |
| WO-2026090557-A1 | SYSTEMS AND METHODS FOR PROCESSING ISM AND MCAS CLINICAL TRIAL DATA | TELIOS PHARMA INC. (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4725506-A2 | THE PEPTIDOMIMETIC COMPOUND (R)-2-AMINO-N-((S)-L-(((S)-5-AMINO-L-(3-BENZYL-1,2,4-OXADIAZOL-5-YL)PENTYL)AMINO)-3-(4-HYDROXY-2,6-DIMETHYLPHENYL)-1-OXOPROPAN-2-YL)-5-GUANIDINOPENTANAMIDE FOR USE IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | Stealth BioTherapeutics Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| WO-1994020103-A1 | USE OF RILUZOLE FOR TREATING AIDS-RELATED NEURAL DISORDERS | RHONE-POULENC RORER S.A. (FR) | 1994-09-15 | — | — | WO | claimed |
| WO-1994015601-A1 | APPLICATION OF RILUZOLE IN THE TREATMENT OF PARKINSON'S DISEASE AND PARKINSONIAN SYNDROMES | RHONE-POULENC RORER S.A. (FR) | 1994-07-21 | — | — | WO | claimed |
| WO-1994015600-A1 | APPLICATION OF RILUZOLE AS A RADIORESTORER | RHONE-POULENC RORER S.A. (FR) | 1994-07-21 | — | — | WO | claimed |
| WO-1994013288-A1 | APPLICATION OF RILUZOLE IN THE TREATMENT OF NEUROLOGICAL LESIONS RELATED TO TRAUMATIC INJURIES | RHONE-POULENC RORER S.A. (FR) | 1994-06-23 | — | — | WO | claimed |
| EP-0374041-B1 | MEDICAMENTS CONTAINING 2-BENZOTHIAZOLAMINE DERIVATIVES, COMPOUNDS AND THEIR PREPARATION | RHONE-POULENC SANTE (FR) | 1992-06-17 | — | — | EP | claimed |
| US-4906649-A | Use of riluzole | RHONE-POULENC SANTE (FR) | 1990-03-06 | — | — | US | claimed |
| US-4882345-A | Use of a compound for the treatment of schizophrenia | RHONE-POULENC SANTE (FR) | 1989-11-21 | — | — | US | claimed |
| US-4826860-A | STROKES | WARNER-LAMBERT COMPANY (US) | 1989-05-02 | — | — | US | claimed |
| EP-0282971-A2 | Substituted 2-aminobenzothiazoles and derivatives useful as cerebrovascular agents | WARNER-LAMBERT COMPANY (US) | 1988-09-21 | — | — | EP | claimed |
| US-4370338-A | ANTICONVULSANT, ANXIOLYTIC, AND HYPNOTIC; RILUZOLE | PHARMINDUSTRIE (FR) | 1983-01-25 | — | — | US | claimed |